Very recently, we experienced a type 2 diabetic patients with CKD stage G4 whose serum creatinine and estimated glomerular filtration rate (eGFR) were remarkably improved by the additional use of dotinurad to SGLT2 inhibitor, GLP-1RA, angiotensin receptor blocker (ARB), and MRA, finerenone [24]. This evidence concerns the gene SLC5A2 and chronic kidney disease.